Yahoo
NasdaqGS - Delayed Quote USD

Lifecore Biomedical, Inc. (LFCR)

6.37 +0.01 (+0.16%)
At close: November 9 at 4:00:00 PM EST
6.37 -0.01 (-0.08%)
After hours: November 9 at 4:01:38 PM EST
Trade LFCR on Coinbase
Chart Range Bar
Loading chart for LFCR
Chart does not reflect overnight price.
  • Previous Close 6.36
  • Open 6.36
  • Bid 4.59 x 200
  • Ask 8.16 x 200
  • Day's Range 6.36 - 6.39
  • 52 Week Range 3.63 - 8.98
  • Volume 142,904
  • Avg. Volume 403,764
  • Market Cap (intraday) 241.46M
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -1.27
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 6.28
  • Moby Rating Bear

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

www.lifecore.com

382

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LFCR
22.13%
S&P 500 (^GSPC)
10.29%

1-Year Return

LFCR
7.01%
S&P 500 (^GSPC)
12.20%

3-Year Return

LFCR
9.90%
S&P 500 (^GSPC)
73.67%

5-Year Return

LFCR
35.00%
S&P 500 (^GSPC)
61.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 25.32M
Earnings -41.02M
Profit Margin -162.01%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-40M
-20M
0
20M
-150.0%
-100.0%
-50.0%

Analyst Insights

View More

Analyst Price Targets

6.28 Low
6.28 Average
6.37 Current
6.28

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/29/2026
Analyst Barrington Research
Rating Action Downgrade
Rating Market Perform
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -66.76%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    106.46M

  • Net Income Avi to Common (ttm)

    -74.94M

  • Diluted EPS (ttm)

    -1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.04M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: